covid
Deep Dive/ Sales and Marketing/ Views & Analysis/ Views and analysis
Refining digital collaboration
mike.hammerton@pharmaphorum.com
Communications and Commercialisation, covid, Deep Dive, Deep Dive: Communications and Commercialisation, impetus, Natalie Yeadon
0 Comment
Oncology/ Views & Analysis/ Views and analysis
Blood Cancer UK: Hopes for our community’s future in the time of COVID
Kate Keightley
blood cancer, Blood Cancer UK, covid, Gilead, Kite, patients
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
Cancer research faces uncertain post-COVID landscape
mike.hammerton@pharmaphorum.com
cancer research, covid, Deep Dive, Deep Dive: Oncology, Oncology, Paul Workman, The Institute of Cancer Research
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
Oncology and a year of COVID: lessons for the future
mike.hammerton@pharmaphorum.com
covid, Deep Dive, Deep Dive: Oncology, Frances O’Connor, Lucid, Lucid Group, Oncology, pandemic
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
How hybrid virtual engagement is accelerating oncology communication
mike.hammerton@pharmaphorum.com
communication, covid, Deep Dive, Deep Dive: Oncology, Mike Abbadessa, Natalie DiMambro, Oncology, Sarah Diffen, Within3
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
Why pharma shouldn’t forget about sites in a post-COVID world
mike.hammerton@pharmaphorum.com
covid, Deep Dive, Deep Dive: Oncology, Oncology, syneos health
0 Comment
Digital/ Views & Analysis/ Views and analysis
Keeping clinical trial data safe – handling cybersecurity in a risky world
Catherine Longworth
clinical trials, covid, cyber attacks, cyber crime, cyber security
0 Comment
Deep Dive/ R&D/ Views & Analysis/ Views and analysis
Inside the UK’s leading efforts to restart clinical research
mike.hammerton@pharmaphorum.com
Clinical Research Network, covid, CRN, Deep Dive, National Institute for Health Research, NHS, NIHR, R&D, Research and Development 2021
0 Comment